<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517997</url>
  </required_header>
  <id_info>
    <org_study_id>20884/25-8-11</org_study_id>
    <nct_id>NCT01517997</nct_id>
  </id_info>
  <brief_title>Infrapopliteal Drug Eluting Angioplasty Versus Stenting</brief_title>
  <acronym>IDEAS-I</acronym>
  <official_title>Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-segment Arterial Disease: The IDEAS-I Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In total 50 patients diagnosed with long-segment infrapopliteal arterial disease will be
      randomized in two groups. The patients randomized in the Drug coated balloons (DCB) study arm
      will undergo a percutaneous transluminal angioplasty (PTA) with the use of a
      paclitaxel-coated balloon, while the patients randomized in the drug-eluting stent (DES)
      study arm will undergo primary stenting using drug-eluting stent(s). The study's primary
      endpoints will be the 6-month angiographic binary restenosis rate. Secondary endpoints will
      include the immediate technical success,6-month primary patency, target lesion
      revascularization and limb salvage and complication rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients programmed to undergo PTA due to angiographically-proven infrapopliteal arterial
      disease in our department will be randomized in the above mentioned study arms. The studies
      primary endpoint will be assessed with the use of intra-arterial digital subtracted
      angiography and subsequent Quantitative Vascular Analysis (QVA) analysis.Clinical follow-up
      is set at 1, 3 and 6 months. Patients' baseline demographics and procedural details will be
      recorded and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic Binary Restenosis</measure>
    <time_frame>6 months</time_frame>
    <description>Angiographic binary restenosis of the target lesion defined by quantitative vessel analysis at 6 months follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>intra-procedural</time_frame>
    <description>Successful balloon angioplasty without stent use due to flow limiting dissection or/and &lt;30% remaining target lesion stenosis in the DCB arm and successful balloon angioplasty without flow limiting dissection or/and &lt;30% remaining target lesion stenosis in the DES arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related complication rates</measure>
    <time_frame>up to 30 days</time_frame>
    <description>procedure related major and minor complication rates identified during the procedure or within 30 days after the completion of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>Clinically-driven target lesion re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb salvage</measure>
    <time_frame>6 months</time_frame>
    <description>Major amputation-free interval of the treated limb at 6 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>Angiographically proven target lesion patency without any additional revascularization procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Arterial Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>Drug Coated Balloon (DCB) Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Eluting Stents (DES) Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paclitaxel coated balloon angioplasty.</intervention_name>
    <description>Infrapopliteal angioplasty using a paclitaxel coated balloon.</description>
    <arm_group_label>Drug Coated Balloon (DCB) Arm</arm_group_label>
    <other_name>DCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infrapopliteal Primary Drug Eluting Stenting</intervention_name>
    <description>Infrapopliteal primary stenting using drug-eluting stent(s)</description>
    <arm_group_label>Drug Eluting Stents (DES) Arm</arm_group_label>
    <other_name>DES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiographically documented infrapopliteal disease.

          -  Rutherford category of peripheral arterial disease between class 3 to 6

          -  Lesion length between 70 to 220 mm

          -  Lesions situated in the proximal, mid and mid to distal segments of the tibial
             vessels.

        Exclusion Criteria:

          -  Lesion length &lt; 70 mm or &gt; 220 mm.

          -  Lesions situated in the distal third of the tibial vessels
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Siablis, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitrios Karnabatidis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstantinos Katsanos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stavros Spiliopoulos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Diamantopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Patras Univesrity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Panagiotis Kitrou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Rion</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>SIABLIS DIMITRIOS</investigator_full_name>
    <investigator_title>Professor of RAdiology</investigator_title>
  </responsible_party>
  <keyword>Drug coated balloons</keyword>
  <keyword>Drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

